These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 18360651)

  • 1. Infliximab (Remicade) in the treatment of psoriatic arthritis.
    Mease P
    Ther Clin Risk Manag; 2006 Dec; 2(4):389-400. PubMed ID: 18360651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
    Tobin AM; Kirby B
    BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newly available treatments for psoriatic arthritis and their impact on skin psoriasis.
    Galadari H; Fuchs B; Lebwohl M
    Int J Dermatol; 2003 Mar; 42(3):231-7. PubMed ID: 12653923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis.
    Krueger G; Callis K
    Arch Dermatol; 2004 Feb; 140(2):218-25. PubMed ID: 14967799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of psoriasis and psoriatic arthritis.
    Papoutsaki M; Costanzo A
    BioDrugs; 2013 Jan; 27 Suppl 1():3-12. PubMed ID: 23990277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
    Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
    Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
    Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
    Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine blockers in psoriatic arthritis.
    Mease PJ
    Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii37-40. PubMed ID: 11890650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.
    Elyoussfi S; Thomas BJ; Ciurtin C
    Rheumatol Int; 2016 May; 36(5):603-12. PubMed ID: 26892034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.
    Caso F; Cantarini L; Morisco F; Del Puente A; Ramonda R; Fiocco U; Lubrano E; Peluso R; Caso P; Galeazzi M; Punzi L; Scarpa R; Costa L
    Expert Opin Biol Ther; 2015 May; 15(5):641-50. PubMed ID: 25652590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Golimumab for the treatment of psoriatic arthritis.
    Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
    Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis.
    Caso F; Lubrano E; Del Puente A; Caso P; Peluso R; Foglia F; Benigno C; Girolimetto N; Bottiglieri P; Scarpa R; Costa L
    Expert Rev Clin Immunol; 2016; 12(3):315-31. PubMed ID: 26558483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine profiles during infliximab monotherapy in psoriatic arthritis.
    Mastroianni A; Minutilli E; Mussi A; Bordignon V; Trento E; D'Agosto G; Cordiali-Fei P; Berardesca E
    Br J Dermatol; 2005 Sep; 153(3):531-6. PubMed ID: 16120138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?
    Megna M; Ocampo-Garza SS; Potestio L; Fontanella G; Gallo L; Cacciapuoti S; Ruggiero A; Fabbrocini G
    Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Off-label dermatologic uses of anti-TNF-a therapies.
    Alexis AF; Strober BE
    J Cutan Med Surg; 2005 Dec; 9(6):296-302. PubMed ID: 16699906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
    Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Four cases of Japanese patients with psoriatic arthritis in whom effective treatments by anti-tumor necrosis factor-α drugs were evaluated by magnetic resonance imaging together with improvement of skin lesions.
    Yonenaga T; Saeki H; Nakagawa H; Fukuchi O; Umezawa Y; Hayashi M; Ito T; Yanaba K; Tojyo S; Fukuda K
    J Dermatol; 2015 Jan; 42(1):49-55. PubMed ID: 25425546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.